Medicare Enrolled

Dr. David Brown, MD

Rheumatology · Hyannis, MA
Practice pattern: Mixed Practice — Diverse clinical practice across multiple procedure types
Low-engagement
700 ATTUCKS LN UNIT 1C, Hyannis, MA 02601
5087718246
In practice since 2006 (20 years)
NPI: 1225071962 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Brown from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Brown? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Brown

Dr. David Brown is a rheumatology specialist in Hyannis, MA, with 20 years of NPI registration. Based on federal Medicare data, Dr. Brown performed 83,736 Medicare services across 1,608 unique beneficiaries.

Between the years covered by Open Payments, Dr. Brown received a total of $54,306 from 44 pharmaceutical and/or device companies across 1174 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in rheumatology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Brown is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 20 years in practice ▲ Top 4% volume in MA $54,306 industry payments

Medicare Practice Summary

Medicare Utilization ↗
83,736
Medicare services
Top 4% in MA for rheumatology
1,608
Unique beneficiaries
$12
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~4,187 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Tocilizumab injection (Actemra) 41,000 $5 $20
Golimumab infusion (Simponi Aria)
Administration of golimumab medication directly into a vein. This code specifies the dosage amount of 1 milligram for intravenous delivery.
21,800 $10 $150
Denosumab injection (Prolia/Xgeva) 10,500 $18 $60
Abatacept infusion (Orencia)
An injection of abatacept administered under the direct supervision of a physician. This code is used for Medicare when the drug is not self-administered.
6,600 $34 $100
Office visit, established patient (20-29 min)
An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition.
914 $66 $250
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
870 $96 $400
Hymovis intra-articular injection
An injection of Hymovis, a hyaluronan derivative, administered directly into a joint space.
792 $13 $150
Intravenous chemotherapy infusion, 1 hour or less
Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete.
268 $106 $1,000
Drug injection, under skin or into muscle
A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle.
229 $11 $250
New patient office visit (30-44 min)
An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range.
182 $86 $500
Additional hour of intravenous chemotherapy
This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period.
114 $22 $400
Joint injection, major joint
Removal of fluid from a large joint and/or injection of medication into the joint space.
110 $50 $450
Methylprednisolone acetate injection, 80 mg
An injection of 80 mg of methylprednisolone acetate, a corticosteroid medication.
104 $9 $30
Intravenous infusion, 1 hour or less
Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less.
97 $42 $550
New patient office visit (45-59 min)
An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter.
81 $131 $600
Zoledronic acid injection, 1 mg
An injection of zoledronic acid administered at a dose of 1 mg.
60 $7 $650
Ultrasound-guided large joint aspiration or injection
This procedure uses ultrasound imaging to guide the removal of fluid from or the injection of medication into a large joint.
15 $83 $1,100
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
34.4% high complexity
63.2% medium
2.4% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$54,306
Total received (2018-2024)
Avg $7,758/year across 7 years
Top 12% in MA for rheumatology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
44
Companies
1,174
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$29,257 (53.9%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$20,434 (37.6%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$4,615 (8.5%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$5,502
2023
$5,615
2022
$4,627
2021
$4,132
2020
$7,292
2019
$23,527
2018
$3,611

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Amgen Inc.
$1,252
Janssen Biotech, Inc.
$694
ABBVIE INC.
$612
UCB, Inc.
$577
Mallinckrodt Hospital Products Inc.
$402
Novartis Pharmaceuticals Corporation
$378
AstraZeneca Pharmaceuticals LP
$299
Lilly USA, LLC
$271
Genentech USA, Inc.
$188
PFIZER INC.
$179
SOBI, INC
$111
E.R. Squibb & Sons, L.L.C.
$91
Fresenius Kabi USA, LLC
$86
Boehringer Ingelheim Pharmaceuticals, Inc.
$80
ANI Pharmaceuticals, Inc.
$78
GENZYME CORPORATION
$74
Sandoz Inc.
$70
GlaxoSmithKline, LLC.
$35
Takeda Pharmaceuticals U.S.A., Inc.
$22
Top 3 companies account for 46.5% of 2024 payments
All-time payments by company (2018-2024) ›
Novartis Pharmaceuticals Corporation
$25,972
Amgen Inc.
$5,044
Janssen Biotech, Inc.
$4,305
Lilly USA, LLC
$2,159
UCB, Inc.
$1,774
Genentech USA, Inc.
$1,694
Mallinckrodt Hospital Products Inc.
$1,311
PFIZER INC.
$1,303
AbbVie Inc.
$1,167
ABBVIE INC.
$1,071
Janssen Scientific Affairs, LLC
$970
Horizon Therapeutics plc
$897
AbbVie, Inc.
$864
AstraZeneca Pharmaceuticals LP
$787
GlaxoSmithKline, LLC.
$709
Regeneron Healthcare Solutions, Inc.
$674
Boehringer Ingelheim Pharmaceuticals, Inc.
$490
E.R. Squibb & Sons, L.L.C.
$464
Sobi, Inc
$295
Fresenius Kabi USA, LLC
$281
SOBI, INC
$266
Horizon Pharma plc
$187
Genentech, Inc.
$160
Bioventus LLC
$149
Takeda Pharmaceuticals U.S.A., Inc.
$142
GENZYME CORPORATION
$125
FIDIA PHARMA USA INC.
$116
ANI Pharmaceuticals, Inc.
$97
Antares Pharma, Inc.
$96
Celgene Corporation
$90
Organon LLC
$88
Flexion Therapeutics, Inc.
$87
Radius Health, Inc.
$77
Sandoz Inc.
$70
SANOFI-AVENTIS U.S. LLC
$61
Ultragenyx Pharmaceutical Inc.
$43
MEDAC PHARMA, INC.
$40
Fidia Pharma USA Inc.
$35
Exeltis, USA Inc.
$30
Alexion Pharmaceuticals, Inc.
$27
Ironwood Pharmaceuticals, Inc
$24
Aurinia Pharma U.S., Inc.
$23
Novo Nordisk Inc
$22
Baudax Bio Inc.
$16
Top 3 companies account for 65.0% of all-time payments
Associated products mentioned in payments ›
ACTHAR · ANJESO · AVSOLA · Actemra · BENLYSTA · BEOVU · Bimzelx · CHANTIX · COSENTYX · CYLTEZO · Cimzia · Crysvita · DUZALLO · Durolane · ELIQUIS · ENTYVIO · EVENITY · Enbrel · FORTEO · GELSYN 3 · GELSYN-3 · HADLIMA · HUMIRA · HYMOVIS · HYRIMOZ · Humira · Hymovis · IDACIO · ILARIS · INFLECTRA · KEVZARA · KEVZARA SARILUMAB INJECTION · KINERET · KRYSTEXXA · Kineret · LUPKYNIS · LYRICA · NUCALA · OFEV · OLUMIANT · ORENCIA · OTREXUP · Otezla · Ozempic · PURIFIED CORTROPHIN GEL · Prolia · REMICADE · RENFLEXIS · RINVOQ · Rasuvo · Rinvoq · Rituxan · SAPHNELO · SIMPONI · SIMPONI ARIA · SKYRIZI · STELARA · SYNVISC-ONE · Supartz · TALTZ · TAVNEOS · TREMFYA · Tavneos · Tymlos · ULTOMIRIS · Uloric · XELJANZ · XYOSTED · Zilretta
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (54%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Looking for a rheumatology specialist in Hyannis?
Compare rheumatologists in the Hyannis area by procedure volume, costs, and industry payment transparency.
Browse rheumatologists nearby

Geographic Context

Rheumatologists within 10 mi
9
Per 100K population
3.9
County median income
$94,452
Nearest hospital
CAPE COD HOSPITAL
0.0 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Brown is a mixed practice specialist, with above-average Medicare volume (top 4% in MA), with low-engagement industry engagement in the top 12% of MA peers, with 20 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Brown experienced with tocilizumab injection (actemra)?
Based on Medicare claims data, Dr. Brown performed 41,000 tocilizumab injection (actemra) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Brown receive payments from pharmaceutical companies?
Yes. Dr. Brown received a total of $54,306 from 44 companies across 1,174 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Brown's costs compare to other rheumatologists in Hyannis?
Dr. Brown's average Medicare payment per service is $12. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Brown) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →